Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria. This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficac ....Enabling aerosol delivery of phages to defeat antibiotic-resistant bacteria. This project aims to explore the use of bacteriophages towards producing a safe, natural, and highly effective alternative to traditional antibiotics. Respiratory infections caused by multidrug-resistant Gram-negative bacteria are a major health problem worldwide, and cost Australia over $150 million annually. Some 5,000 Australians die each year from antibiotic resistant infections. The project aims to produce efficacious and stable formulations of bacteriophages for easy delivery by inhalation as aerosols with a long shelf-life, making them a commercially viable product. The expected research outcome can lead to an economic and efficient technology to produce phage powders for novel treatment strategies of infections by inhalation.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0668493
Funder
Australian Research Council
Funding Amount
$230,000.00
Summary
Characterising particulate laden flow in the lung airways: from drug delivery to primary anthropogenic sources. Facilities will provide infrastructure at Monash University and University of Sydney to continue the collaboration enhancing excellence in an exciting application of fluidics research, supporting the highest level of graduate training, providing innovative tools for industry and promoting industrial collaborations. The infrastructure is unique and will create international funding and ....Characterising particulate laden flow in the lung airways: from drug delivery to primary anthropogenic sources. Facilities will provide infrastructure at Monash University and University of Sydney to continue the collaboration enhancing excellence in an exciting application of fluidics research, supporting the highest level of graduate training, providing innovative tools for industry and promoting industrial collaborations. The infrastructure is unique and will create international funding and collaborative opportunities to support research and postgraduate training. The equipment will add value to existing infrastructure to enhance understanding of particulate flow with the paradoxical outcomes of improving drug deposition in respiratory delivery and of minimising anthropogenic particular deposition for better therapeutic and health outcomes.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0560661
Funder
Australian Research Council
Funding Amount
$245,300.00
Summary
Particulate Characterisation for Pharmaceutical and Engineering Applications. The aim of this proposal is to establish joint facilities between the University of Sydney, Monash University and UNSW for the characterization of surface properties and particle sizes of pharmaceutical aerosols and industrial powders. Such knowledge is important for controlling aerosol production and delivery of drug particles to the lungs. This will have a significant benefit to the pharmaceutical industry and patien ....Particulate Characterisation for Pharmaceutical and Engineering Applications. The aim of this proposal is to establish joint facilities between the University of Sydney, Monash University and UNSW for the characterization of surface properties and particle sizes of pharmaceutical aerosols and industrial powders. Such knowledge is important for controlling aerosol production and delivery of drug particles to the lungs. This will have a significant benefit to the pharmaceutical industry and patients requiring aerosol treatment. Further, the proposed facilities will enhance research in complex particulate processes and modelling, functional nanomaterials, and soft sensor development, thus keeping Australia at the forefront of powder research into various high value adding particulate areas.Read moreRead less
Engineering of co-crystal drug molecules for pharmaceutical aerosols. This project will enable Australia to become a world leader in treatment of respiratory diseases. The Australian financial burden of respiratory diseases is currently estimated as $900m with significant impact on infrastructure (through regular clinical visits, hospitalisation and workforce loss). The global market for the treatment of COPD is currently $32 billion and is expected to increase significantly by 2010. The positio ....Engineering of co-crystal drug molecules for pharmaceutical aerosols. This project will enable Australia to become a world leader in treatment of respiratory diseases. The Australian financial burden of respiratory diseases is currently estimated as $900m with significant impact on infrastructure (through regular clinical visits, hospitalisation and workforce loss). The global market for the treatment of COPD is currently $32 billion and is expected to increase significantly by 2010. The positioning of an Australian research as a world leader in the development of new treatments will have significant national benefit, whilst the sector will benefit for scientific advancements that arise during this project.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0775720
Funder
Australian Research Council
Funding Amount
$100,000.00
Summary
State-of-the-art high resolution thermal analysis suite for the life and material sciences. The facility, unique in Australia, will ensure that Australia will retains in a leading position in these research fields, will provide a basis to be competitive in international funding and support postgraduate training. The acquired equipments will strengthen the already existing infrastructures, enhancing understanding of intrinsic physico-chemical characteristic of various materials, to benefit the co ....State-of-the-art high resolution thermal analysis suite for the life and material sciences. The facility, unique in Australia, will ensure that Australia will retains in a leading position in these research fields, will provide a basis to be competitive in international funding and support postgraduate training. The acquired equipments will strengthen the already existing infrastructures, enhancing understanding of intrinsic physico-chemical characteristic of various materials, to benefit the community such as characterising functional nanomaterials for high-tech technologies and use of inhalation aerosol drug delivery to benefit patients with respiratory diseases for an improved therapeutic and health outcome.Read moreRead less
Dispersion of Pharmaceutical Powders as Aerosols for Inhalation. The detrimental environmental effects of chlorofluorocarbons (CFC) have led to an urgent need of a replacement for the existing CFC propellant driven medical inhalers. Generation of aerosols from dry powders has enormous potential as an alternative for delivery of drugs to the lung. The aims of the proposed research are to investigate specifically the powder surface properties and the orperating conditions on the dispersion of po ....Dispersion of Pharmaceutical Powders as Aerosols for Inhalation. The detrimental environmental effects of chlorofluorocarbons (CFC) have led to an urgent need of a replacement for the existing CFC propellant driven medical inhalers. Generation of aerosols from dry powders has enormous potential as an alternative for delivery of drugs to the lung. The aims of the proposed research are to investigate specifically the powder surface properties and the orperating conditions on the dispersion of powders as aerosols for inhalation. The knowledge gained will acclerate the design of better powder aerosols, thus benefiting patients suffering from respiratory and systemic diseases.Read moreRead less
Mannitol Powders for Assessment of Asthma in Children. A successful conclusion of this project will enable Australia to become a world leader in childhood asthma assessment. The availability of an objective diagnostic test for early detection of asthma would assist formulating early treatment strategies at this crucial stage in the progression of the disease, improving the quality of life of asthma sufferers in their early years. The Australian pharmaceutical sector will benefit through the ab ....Mannitol Powders for Assessment of Asthma in Children. A successful conclusion of this project will enable Australia to become a world leader in childhood asthma assessment. The availability of an objective diagnostic test for early detection of asthma would assist formulating early treatment strategies at this crucial stage in the progression of the disease, improving the quality of life of asthma sufferers in their early years. The Australian pharmaceutical sector will benefit through the ability to develop proprietary formulations targeted towards taking advantages of the scientific knowledge on pharmaceutical powders and aerosols. The mannitol testing is environmental friendly as powder aerosol delivery does not require any harmful organic solvents to operate.Read moreRead less
Engineering a delivery device and development of a novel formulation for chronic obstructive pulmonary disease and cystic fibrosis. This project will position Australia to become one of the world leaders in the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other chronic respiratory diseases. The financial burdens of COPD and CF come to at least $900 million a year in Australia alone. These diseases have significant impact on patients and the health system th ....Engineering a delivery device and development of a novel formulation for chronic obstructive pulmonary disease and cystic fibrosis. This project will position Australia to become one of the world leaders in the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other chronic respiratory diseases. The financial burdens of COPD and CF come to at least $900 million a year in Australia alone. These diseases have significant impact on patients and the health system through regular clinical visits, hospitalisation and employment downtime. The global market for the treatment of COPD is currently more than $8 billion and is expected to increase substantially. The positioning of an Australian pharmaceutical company at the forefront of COPD/CF treatment will have significant national benefits for patients, the health system, and research infrastructure in the field.Read moreRead less
Advanced nanotechnologies for targeting biofilms. Advanced nanotechnologies for targeting biofilms. This project aims to develop nano-particulate systems based on a single platform technology that can be delivered as an aerosol. The current lack of a suitable formulation and delivery system hinders the eradication of fungal and bacterial biofilms from surfaces. These new systems will have enhanced residency time, penetration properties and effectiveness in biofilms. This project intends to under ....Advanced nanotechnologies for targeting biofilms. Advanced nanotechnologies for targeting biofilms. This project aims to develop nano-particulate systems based on a single platform technology that can be delivered as an aerosol. The current lack of a suitable formulation and delivery system hinders the eradication of fungal and bacterial biofilms from surfaces. These new systems will have enhanced residency time, penetration properties and effectiveness in biofilms. This project intends to understand the properties that govern the formation and interactions in these systems, and develop in-vitro tools that the wider scientific community can use. The project expects to generate a single platform that can be used for the eradication of biofilms in numerous applications, from healthcare to agriculture.Read moreRead less
Smartdrops - Shaping the future of particle technology. The aim of this project is to develop a particle engineering technology, based on microfluidics, that results in micro-droplets with controlled geometry and morphology. These Smartdrops will be used to target respiratory macrophages for the delivery of inflammatory suppressants, since their dimensions can be controlled to optimise lung deposition and macrophage recognition. The project aims to develop an aerosol inhaler and a series of phys ....Smartdrops - Shaping the future of particle technology. The aim of this project is to develop a particle engineering technology, based on microfluidics, that results in micro-droplets with controlled geometry and morphology. These Smartdrops will be used to target respiratory macrophages for the delivery of inflammatory suppressants, since their dimensions can be controlled to optimise lung deposition and macrophage recognition. The project aims to develop an aerosol inhaler and a series of physico-chemical and in vitro characterisation tools that will be used to study Smartdrop formation, aerosol properties and their interactions with cells. The outcome of this project is intended to be the development of a technology for treating chronic lung inflammation which could also be utilised for a number of other commercial applications.Read moreRead less